A meta-regression study suggested a linear relationship between HbA1c reduction and MACE risk in patient with arGLP-1.89 Publication on mediation analyses also suggest that cardiovascular benefit could be mediated in part by effects on HbA1c, on blood pressure or reduction in urine albumin-creatinine ratio90,91 (see below), as well as by their effect on lipid profile.81 However, in subgroup analyses of cardiovascular safety studies, baseline HbA1c, weight, previous cardiovascular disease, or renal function did not predict the beneficial effects of these drugs on MACE,87 so other mechanisms, such as the previously mentioned anti-inflammatory, antifibrotic, antiatherogenic, vasodilator, or endothelial function-enhancing effects, have been suggested to influence the cardiovascular benefit of these drugs29,78 (Fig
Detailed return instructions further reassure customers, boosting confidence and encouraging more sales
Adequate protein intake (around 1.6 g per kg of body weight if you're training), two or three resistance sessions a week, consistent sleep, and addressing any underlying issues (thyroid, testosterone, iron) before reaching for a peptide
In addition, GLP-1 therapies affect body composition by reducing not only fat mass but also lean mass, a concern that is particularly relevant for at-risk groups such as older patients and those with sarcopenic obesity [[7], [8], [9]]
